Who are amifostine trihydrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zinecard, Blenoxane, BNP7787.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amifostine-trihydrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

amifostine trihydrate — Competitive Intelligence Brief

amifostine trihydrate (amifostine trihydrate) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytoprotective agent. Area: Oncology.

marketed Cytoprotective agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

amifostine trihydrate (amifostine trihydrate) — City of Hope Medical Center. Amifostine is a prodrug that is converted to an active free thiol compound, which acts as a cytoprotective and radioprotective agent by scavenging free radicals and reducing DNA damage.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
amifostine trihydrate TARGET	amifostine trihydrate	City of Hope Medical Center	marketed	Cytoprotective agent
Zinecard	DEXRAZOXANE	Pfizer	marketed	Cytoprotective Agent	DNA topoisomerase 2-alpha	1995-01-01
Blenoxane	BLEOMYCIN	Bristol-Myers Squibb	marketed	Cytoprotective Agent	Aspartyl/asparaginyl beta-hydroxylase	1973-01-01
BNP7787	BNP7787	Alliance for Clinical Trials in Oncology	phase 3	Cytoprotective agent / Cisplatin protectant	Cisplatin (indirect; forms inactivating complex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytoprotective agent class)

City of Hope Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). amifostine trihydrate — Competitive Intelligence Brief. https://druglandscape.com/ci/amifostine-trihydrate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab